Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sotorasib + AMG 404
- Development stage
- Unknown
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**Sotorasib + AMG 404** is an investigational combination therapy for cancer treatment, currently studied in advanced solid tumors (especially non-small cell lung cancer with KRAS G12C mutation). Sotorasib is a small molecule that selectively and irreversibly inhibits the KRAS G12C mutant protein, blocking KRAS-dependent signaling pathways and thereby inhibiting tumor growth. AMG 404 is a fully human immunoglobulin G1 (IgG1) monoclonal antibody directed against the programmed cell death 1 (PD-1) receptor; it blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2, thereby promoting immune-mediated anti-tumor activity. The combination seeks to maximize anti-tumor efficacy by simultaneously targeting oncogenic signaling (KRAS G12C) and enhancing immune response via checkpoint inhibition. Both agents are developed by Amgen[2][3][5].
- Other names
- sotorasib + AMG 404
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)KRASG12C (Kirsten rat sarcoma viral oncogene homolog G12C)
Beyond the preview
Go deeper on sotorasib + AMG 404.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sotorasib + AMG 404.